Develops, manufactures, and sells medicines for people with serious diseases.
10-K for FY2025, filed Feb 4, 2026Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes…View ↗
Most revenue comes from collaborations (51%): partners share product profits, reimburse research and manufacturing costs, and pay royalties or sales milestones. Regeneron also sells medicines, with revenue tied to customer receipt or acceptance.
10-K for FY2025, filed Feb 4, 2026If our collaborator performs research and development work or commercialization-related activities and the parties share the related costs…View ↗
supply commercial product to our collaborator, we may be reimbursed for our manufacturing costs as commercial product is shipped to the…View ↗
We recognize revenue from product sales at a point in time when our customer is deemed to have obtained control of the product, which…View ↗
$14.3B
10-K for FY2025, filed Feb 4, 2026
$14.3B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Net product sales
Sold outright
10-K for FY2025, filed Feb 4, 2026 |
44%
FY2022: 57%
|
Net product sales, FY2025
$6.3B Sources
|
Sold outright |
|
Collaboration revenue
|
51%
FY2022: 40%
|
Collaboration revenue, FY2025
$7.3B Sources
|
|
|
Other revenue
|
4.9%
FY2022: 3.0%
|
Other revenue, FY2025
$702.6M Sources
|
Product customers include distributors and specialty pharmacies, and the company also sells at discounted prices to qualified healthcare providers. Collaborators work with Regeneron on research, development, manufacturing, and commercialization.
10-K for FY2025, filed Feb 4, 2026
Yes. It kept 31 cents of every revenue dollar as net income in FY2025 and turned 28 cents into free cash flow.
10-Q for Q3 FY2026, filed Oct 30, 2026
Open tableView ↗
Shrinking. Revenue fell 11% in 4 years, from $16.1B in FY2021 to $14.3B in FY2025, about 3% a year.
Competes with Outlook Therapeutics, Novartis, AbbVie, Alimera Sciences, Amgen, Sandoz, Sam Chun Dang, Samsung Bioepis, Harrow, Xbrane Biopharma, STADA Arzneimittel, Formycon, Bioeq, Teva, Zydus Lifesciences, Almirall, Eli Lilly, Pfizer, AstraZeneca, and GSK
10-K for FY2025, filed Feb 4, 2026Outlook Therapeutics, Inc.View ↗
Loading...